Review| Volume 75, ISSUE 11, P4281-4289, November 2022

Is deoxycholic acid able to reduce submental fat and increase patient satisfaction when compared to placebo groups? A systematic review

Published:August 17, 2022DOI:


      The accumulation of submental fat (SMF) can negatively impact facial harmony appearance, and one alternative treatment for this condition is the application of deoxycholic acid (DOC). The objective of this systematic review was to answer the following question: “Is DOC able to reduce SMF and increase patient satisfaction when compared to the placebo groups?”. Therefore, a detailed search strategy was carried out in 6 scientific databases (PubMed, Scopus, Embase, Lilacs, SciELO, and Web of Science) as primary search sources, while OpenGrey and OpenThesis were also used to capture the “grey literature”. Only six studies met all inclusion criteria and were considered in this review analysis. The selected sample included prospective clinical studies published from 2014 to 2018, covering a total sample of 3488 patients, with an average age ranging from 46 to 49.5 years old. All selected articles evaluated the effect of DOC at concentrations of 1 mg/cm² or 2 mg/cm², using saline or placebo as control solutions for the comparative analysis. The application interval was 28 days in all studies analyzed, and the treatment duration ranged from 4 to 6 weeks. In all studies evaluated, there was a reduction in SMF and patient satisfaction with the application of DOC was higher than in the control groups at the end of a 12-week period. Thus, it is possible to conclude that the application of DOC has a positive effect on reducing SMF and improving patient satisfaction concerning their facial appearance.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Humphrey S
        • Sykes J
        • Kantor J
        • et al.
        ATX-101 for reduction of submental fat: A phase III randomized controlled trial.
        J Am Acad Dermatol. 2016; 75: 788-797
        • Grow JN
        • Holding J
        • Korentager R.
        Assessing the Efficacy of Deoxycholic Acid for the Treatment of Submental Fat: A Three-Dimensional Study.
        Aesthet Surg J. 2019; 39: 1400-1411
        • Blandford AD
        • Ansari W
        • Young JM
        • et al.
        Deoxycholic Acid and the Marginal Mandibular Nerve: A Cadaver Study.
        Aesthetic Plast Surg. 2018; 42: 1394-1398
        • Rotunda AM
        • Suzuki H
        • Moy RL
        • Kolodney MS.
        Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution.
        Dermatol Surg. 2004; 30: 1001-1008
        • Ascher B
        • Hoffmann K
        • Walker P
        • Lippert S
        • Wollina U
        • Havlickova B.
        Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study.
        J Eur Acad Dermatol Venereol. 2014; 28: 1707-1715
        • Dover JS
        • Kenkel JM
        • Carruthers A
        • et al.
        Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat [published correction appears in Dermatol Surg 2017;43;1000].
        Dermatol Surg. 2016; 42: S288-S299
        • Dover JS
        • Shridharani SM
        • Bloom JD
        • Somogyi C
        • Gallagher CJ.
        Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results from a Post hoc Analysis.
        Dermatol Surg. 2018; 44: 1477-1479
        • Liberati AD
        • Mulrow C
        • Gotzsche PC
        • Loannidis JP.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ (Clinical Research ed.). 2009; : 339
      1. Cochrane Handbook for systematic Reviews of Interventions. Second Edition, Oxford, UK, 2019.

        • Moola SMZ
        • Tufanaru C
        • Aromataris E
        • et al.
        Chapter 7: Systematic reviews of etiology and risk.
        JBI Manual for Evidence Synthesis. 2020;
        • Rzany B
        • Griffiths T
        • Walker P
        • Lippert S
        • McDiarmid J
        • Havlickova B.
        Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study.
        Br J Dermatol. 2014; 170: 445-453
        • McDiarmid J
        • Ruiz JB
        • Lee D
        • Lippert S
        • Hartisch C
        • Havlickova B.
        Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat.
        Aesthetic Plast Surg. 2014; 38: 849-860
        • Jones DH
        • Carruthers J
        • Joseph JH
        • et al.
        REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction.
        Dermatol Surg. 2016; 42: 38-49
        • Dayan SH
        • Humphrey S
        • Jones DH
        • et al.
        Overview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental Fat.
        Dermatol Surg. 2016; 42: S263-S270
        • Pham CT
        • Lee A
        • Sung CT
        • Choi F
        • Juhasz M
        • Mesinkovska NA.
        Adverse Events of Injectable Deoxycholic Acid.
        Dermatol Surg. 2020; 46: 942-949
        • Brackeen A.
        A template for estimating doses of deoxycholic acid for submental fat fullness.
        J Am Acad Dermatol. 2016; 75: e151-e152
        • Miranda E
        • Hossne WS.
        Clinical trials (phase III) - profile of scientific publications. Bioethical aspects.
        Rev Bras Clin Med. 2010; 8: 143-147